LabCorp announced today that its Covance Drug Development business has entered into a strategic technology agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, GSK will use Covance’s Xcellerate Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions in a software-as-a-service (SaaS) model.

“We are thrilled to have the opportunity to collaborate with GSK,” said Dimitris Agrafiotis, chief data officer and head of technology products at Covance. “Xcellerate is a powerful technology platform that brings data to life to improve clinical-trial decision-making and accelerate trial results. It enables study teams to track the progress of their studies and identify and mitigate potential risks with greater insight and speed.  

A key component of the technology licensed by GSK is Xcellerate Monitoring, Covance’s comprehensive implementation of risk-based monitoring, which enables assessment and mitigation of risk at the study, site and patient level. It also allows sponsors to strategically guide site monitoring resources and build quality and efficiency into their clinical trials, from commencement to completion. As part of the agreement, Covance will support GSK with implementation, starting in the first half of 2018.